About Us


MaxiNovel Pharmaceuticals Co.,Ltd. is a China based biotech company founded in 2016 to focus on the innovative drug research with the global intellectual property rights.

We carry out first-in-class small molecule drug discovery in the areas of targeted therapy and immunotherapy. Our rapidly expanding product pipeline is mainly composed of programs that target both blood tumors and solid tumors as well as autoimmune diseases. Company’s research platforms encompass oral therapy, radiotherapy, imaging and transdermal therapy.

We have our R&D and operation centers in China (Shanghai, Guangzhou, Shenzhen), the United States and Australia.  Our management team members all have extensive previous working experiences in global pharmaceutical companies and capital markets, more importantly global vision of our company’s future development.

Our mission is to conduct pharmaceutical innovation to save lives and bring hopes to patients and their families.



Pipeline

  • Items
  • Preclinical
  • Phase I
  • Phase II
  • MAX-4

    Targeted Therapy
    AML

  • MAX-5

    Targeted Therapy
    Solid tumors

  • MAX-1

    IO Therapy
    Solid tumors

  • MAX-3

    Alopecia Areata
    Atopic Dermatitis

  • MAX-2

    Imaging Solid tumors

  • MAX-8

    Radio-Ligand Therapy

  • MAX-6、7

    Undisclosed
    Solid tumors

Click Show

News

All News